Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 0.64 |
| ▸ | MAOA | P21397 | 9/20 | 0.64 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.64 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.50 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.50 |
| ▸ | KIF11 | P52732 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10509516 | 0.87 | HTT (0.59) | MAOBMAOAEPHX2PDE3BPDE3A | |
| SCHEMBL6754956 | 0.79 | KIF11 (0.68) | MAOBMAOAEPHX2PDE3BPDE3A | |
| SCHEMBL18307137 | 0.78 | MAOB (0.64) | MAOBMAOAEPHX2PDE3BPDE3A | |
| SCHEMBL299571 | 0.78 | MAOB (0.64) | MAOBMAOAEPHX2PDE3BPDE3A | |
| SCHEMBL3599640 | 0.78 | MAOB (0.64) | MAOBMAOAEPHX2PDE3BPDE3A | |
| SCHEMBL7450900 | 0.78 | ALDH1A1 (0.59) | MAOBMAOAEPHX2NOX1ALDH1A1 | |
| SCHEMBL31469916 | 0.78 | MAOB (0.64) | MAOBMAOAEPHX2PDE3BPDE3A | |
| SCHEMBL6015836 | 0.78 | MAOB (1.00) | MAOBMAOAEPHX2PDE3BPDE3A | |
| SCHEMBL279937 | 0.78 | EPHX2 (1.00) | MAOBMAOAEPHX2PDE3BPDE3A | |
| SCHEMBL3599644 | 0.78 | MAOB (0.64) | MAOBMAOAEPHX2PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025077767-A1 | NOVEL I-TYPE TOPOISOMERASE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翊维康医药有限责任公司 | 2025-04-17 | — | — | WO | disclosed |
| US-20230286934-A1 | Use of Multi-Kinase Inhibitors to Treat RNA Virus Infections | ICAHN SCHOOL MED MOUNT SINAI (US) | 2023-09-14 | — | — | US | disclosed |
| US-9242945-B2 | Substituted 2-benzylidene-2H-benzo[b][1,4]thiazin-3(4H)-ones, derivatives thereof, and therapeutic uses thereof | Temple University—Of the Commonwealth System of Higher Education (US) | 2016-01-26 | — | — | US | disclosed |
| US-9242945-B2 | Substituted 2-benzylidene-2H-benzo[b][1,4]thiazin-3(4H)-ones, derivatives thereof, and therapeutic uses thereof | Temple University—Of the Commonwealth System of Higher Education (US) | 2016-01-26 | — | — | US | disclosed |
| EP-2152664-B1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-09-03 | — | — | EP | disclosed |
| US-20140086941-A1 | SUBSTITUTED 2-BENZYLIDENE-2H-BENZO[b][1,4]THIAZIN-3(4H)-ONES, DERIVATIVES THEREOF, AND THERAPEUTIC USES THEREOF | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140086941-A1 | SUBSTITUTED 2-BENZYLIDENE-2H-BENZO[b][1,4]THIAZIN-3(4H)-ONES, DERIVATIVES THEREOF, AND THERAPEUTIC USES THEREOF | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2014-03-27 | — | — | US | disclosed |
| WO-2011151361-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2011-12-08 | — | — | WO | disclosed |
| EP-1419155-B1 | PIPERIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2006-11-08 | — | — | EP | disclosed |
| US-20040198756-A1 | Medicaments | SMITHKLINE BEECHAM PLC (GB) | 2004-10-07 | — | — | US | disclosed |
| EP-1419155-A2 | PIPERIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2004-05-19 | — | — | EP | disclosed |
| WO-2003010138-A2 | PIPERIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2003-02-06 | — | — | WO | disclosed |
| EP-0162776-B1 | HETEROCYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND MEDICAMENTS USEFUL AS ALDOSE REDUCTASE INHIBITORS CONTAINING THEM | LABORATOIRES UPSA (FR) | 1989-04-19 | — | — | EP | disclosed |
| US-4755509-A | Heterocyclic aldose reductase inhibitors and methods of using them | Carbipem (FR) | 1988-07-05 | — | — | US | disclosed |
| EP-0162776-A2 | Heterocyclic derivatives, process for their preparation and medicaments useful as aldose reductase inhibitors containing them | LABORATOIRES UPSA (FR) | 1985-11-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140086941-A1 | SUBSTITUTED 2-BENZYLIDENE-2H-BENZO[b][1,4]THIAZIN-3(4H)-ONES, DERIVATIVES THEREOF, AND THERAPEUTIC USES THEREOF | RB1, AR, CDK4 | MAOB 1316/4885MAOA 3112/4885EPHX2 3468/4885 |
| US-20230286934-A1 | Use of Multi-Kinase Inhibitors to Treat RNA Virus Infections | EIF2AK2, SARS1, ACE2 | MAOB 2784/4885MAOA 3359/4885EPHX2 3226/4885 |
| US-20040198756-A1 | Medicaments | PIGO, PSAP, CD68 | MAOB 3007/4885MAOA 2378/4885EPHX2 4556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.